Loading
A phase 1/2 trial of Gemcitabine, Paclitaxel / nab-paclitaxel in metastatic cancer, run by Verastem, Inc., active and no longer recruiting.
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer is a phase 1/2 interventional study registered as NCT05669482 by Verastem, Inc., with 40 participants planned, started 2023-03-22 and due to reach its primary completion in 2026-08-31. Interventions recorded: avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel. Conditions listed: KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/